A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X [fluticasone furoate] aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects ages 2 to 12 years with seasonal allergic rhinitis

Trial Profile

A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of once-daily, intranasal administration of GW685698X [fluticasone furoate] aqueous nasal spray 50mcg and 100mcg for 2 weeks in pediatric subjects ages 2 to 12 years with seasonal allergic rhinitis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Fluticasone furoate (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2013 Planned patient number is 576 according to ClinicalTrials.gov.
    • 06 Oct 2006 Status change
    • 08 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top